HGH 191AA (somatropin) hGH
Growth hormone axisPrescription medicine WADA · Prohibited (S2.2.3)
Recombinant human growth hormone; approved prescription medicine in many markets.
Monograph plannedAll content is for general information only — not medical advice, not a dosing or usage recommendation, and not a claim of efficacy. Many substances are not approved as medicines or are prescription-only; whether possession and use are legal depends on the law of your country of residence and is your own responsibility. myPeptides does not sell or supply any substances — it is an information and organization tool. For health questions, consult a licensed physician or pharmacist.
Peptide register
Every peptide covered here, with its mechanism class, legal status and WADA status. This is a status register, not a shop: no suppliers, no doses, no efficacy claims.
Class
Legal status
WADA status
Monograph
14 of 73
AOD-9604
Growth hormone axisResearch chemical WADA · Prohibited (S2.2.3)
Growth hormone fragment 176-191; drug development discontinued, no medicine approval.
Holds a food-ingredient status in the US, not a medicine approval
MonographCJC-1295 (no DAC)
Growth hormone axisResearch chemical WADA · Prohibited (S2.2.4)
Growth-hormone-releasing hormone analogue without a drug affinity complex; not approved anywhere.
MonographCJC-1295 DAC
Growth hormone axisResearch chemical WADA · Prohibited (S2.2.4)
Long-acting growth-hormone-releasing hormone analogue; no approval in any market.
MonographGHRP-1
Growth hormone axisResearch chemical WADA · Prohibited (S2.2.4)
Growth-hormone-releasing peptide; single-dose studies in the 1990s, one registered trial abandoned in 2007, no approval anywhere.
MonographGHRP-2
Growth hormone axisPrescription medicine WADA · Prohibited (S2.2.4)
Growth-hormone-releasing peptide; licensed in Japan as a diagnostic agent only.
Japan only, diagnostic use
MonographGHRP-6
Growth hormone axisResearch chemical WADA · Prohibited (S2.2.4)
Growth-hormone-releasing peptide; no approval as a medicine in any market.
MonographHexarelin
Growth hormone axisResearch chemical WADA · Prohibited (S2.2.4)
Growth-hormone-releasing peptide studied in the 1990s; no approval in any market.
MonographIGF-1 LR3
Growth hormone axisResearch chemical WADA · Prohibited (S2.3)
Modified insulin-like growth factor 1 analogue sold for laboratory use; no approval anywhere.
Monograph plannedIpamorelin
Growth hormone axisResearch chemical WADA · Prohibited (S2.2.4)
Selective ghrelin receptor agonist; development discontinued, not approved in any market.
MonographMechano Growth Factor MGF
Growth hormone axisResearch chemical WADA · Prohibited (S2.3)
Splice variant of insulin-like growth factor 1; no registered human trials and no approval.
Monograph plannedPEG-MGF
Growth hormone axisResearch chemical WADA · Prohibited (S2.3)
Pegylated form of a mechano growth factor peptide; no approval in any market.
Monograph plannedSermorelin
Growth hormone axisPrescription medicine WADA · Prohibited (S2.2.4)
GHRH fragment; former US prescription medicine (withdrawn 2009, not for safety), today compounded on prescription only.
Former US prescription medicine, withdrawn 2009 for non-safety reasons; today only compounded on prescription; named in the German prescription-only schedule
MonographTesamorelin
Growth hormone axisPrescription medicine WADA · Prohibited (S2.2.4)
Growth-hormone-releasing hormone analogue; approved prescription medicine for one indication.
MonographTake myPeptides with you
Track doses, plans and progress on your phone — end-to-end encrypted.
This article is for informational purposes only and does not replace medical advice. myPeptides gives no dosing recommendations.